| For: | Lee JS, Lee JH, Lee JH, Lee HJ, Kim MJ, Lee HJ, Choe YH. Efficacy of early treatment with infliximab in pediatric Crohn’s disease. World J Gastroenterol 2010; 16(14): 1776-1781 [PMID: 20380012 DOI: 10.3748/wjg.v16.i14.1776] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v16/i14/1776.htm |
| Number | Citing Articles |
| 1 |
Maria M E Jongsma, Martine A Aardoom, Martinus A Cozijnsen, Merel van Pieterson, Tim de Meij, Michael Groeneweg, Obbe F Norbruis, Victorien M Wolters, Herbert M van Wering, Iva Hojsak, Kaija-Leena Kolho, Thalia Hummel, Janneke Stapelbroek, Cathelijne van der Feen, Patrick F van Rheenen, Michiel P van Wijk, Sarah T A Teklenburg-Roord, Marco W J Schreurs, Dimitris Rizopoulos, Michail Doukas, Johanna C Escher, Janneke N Samsom, Lissy de Ridder. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial. Gut 2022; 71(1) doi: 10.1136/gutjnl-2020-322339
|
| 2 |
Mi Jin Kim, Yon Ho Choe. Recent Trends of Infliximab Treatment for Crohn's Disease. Pediatric Gastroenterology, Hepatology & Nutrition 2012; 15(1) doi: 10.5223/pghn.2012.15.1.19
|
| 3 |
Zinan Zhang, Xiaoyu Yu, Ning Fang, Xiuyan Long, Xixian Ruan, Jianing Qiu, Sifan Tao, Pan Gong, Kai Nie, An Li, Xiaoyan Wang, Li Tian. Can visceral adipose tissue and skeletal muscle predict recurrence of newly diagnosed Crohn’s disease in different treatments. BMC Gastroenterology 2022; 22(1) doi: 10.1186/s12876-022-02327-5
|
| 4 |
M. E. Jacobson, R. S. Seshadri, R. Morimoto, E. Grinich, C. Haag, K. Nguyen, E. L. Simpson. Early intervention and disease modification in atopic dermatitis—the current state of the field and barriers to progress. Journal of the European Academy of Dermatology and Venereology 2024; 38(4) doi: 10.1111/jdv.19699
|
| 5 |
HyunJoo Lim, Ju Hwan Kim, Byong Duk Ye, Bin Hong, Bohyun Suh, Jae-Eun Lee, Yongjing Zhang, Hong Qiu, Ko Nakajo, Ju-Young Shin. Real-world patterns of inflammatory bowel disease treatment across adult and pediatric populations: a nationwide cohort study in South Korea. Frontiers in Medicine 2026; 13 doi: 10.3389/fmed.2026.1883050
|
| 6 |
Ryan C Ungaro, Saurabh Aggarwal, Ozlem Topaloglu, Wan‐Ju Lee, Ryan Clark, Jean‐Frederic Colombel. Systematic review and meta‐analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn’s disease. Alimentary Pharmacology & Therapeutics 2020; 51(9) doi: 10.1111/apt.15685
|
| 7 |
Eric L. Simpson, Amy S. Paller, Oscar Palomares, Thomas Bieber. Defining the Potential for Disease Modification in Atopic Dermatitis. American Journal of Clinical Dermatology 2026; doi: 10.1007/s40257-026-01050-1
|
| 8 |
Enrique Medina. Enfermedad inflamatoria intestinal (II): diagnóstico y tratamiento. Anales de Pediatría Continuada 2013; 11(2) doi: 10.1016/S1696-2818(13)70121-5
|
| 9 |
Parambir S. Dulai, Corey A. Siegel, Marla C. Dubinsky. Balancing and Communicating the Risks and Benefits of Biologics in Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2013; 19(13) doi: 10.1097/MIB.0b013e31829aad16
|
| 10 |
Shiho Sagara, Takeshi Etou, Hiro-o Yamano, Taku Harada, Masahiro Iizuka. Typical gastroduodenal endoscopic findings in a Crohn's disease patient in remission stage. World Journal of Gastrointestinal Endoscopy 2012; 4(3): 96-98 doi: 10.4253/wjge.v4.i3.96
|
| 11 |
Lei Zhang, Zhixiao Jin, Jia Hao. Efficacy of early biologic therapy versus late/conventional therapy in children and adolescents with Crohn’s disease: A systematic review and meta-analysis. Saudi Journal of Gastroenterology 2023; 29(5) doi: 10.4103/sjg.sjg_190_23
|
| 12 |
Charlotte I. de Bie, Johanna C. Escher, Lissy de Ridder. Antitumor necrosis factor treatment for pediatric inflammatory bowel disease. Inflammatory Bowel Diseases 2012; 18(5) doi: 10.1002/ibd.21871
|
| 13 |
Yun Seok Lee, Sang Hun Baek, Mi Jin Kim, Yoo Min Lee, Yoon Lee, Yon Ho Choe. Efficacy of Early Infliximab Treatment for Pediatric Crohn's Disease: A Three-year Follow-up. Pediatric Gastroenterology, Hepatology & Nutrition 2012; 15(4) doi: 10.5223/pghn.2012.15.4.243
|
| 14 |
Rocío Prieto-Pérez, Berta Almoguera, Teresa Cabaleiro, Hakon Hakonarson, Francisco Abad-Santos. Association between Genetic Polymorphisms and Response to Anti-TNFs in Patients with Inflammatory Bowel Disease. International Journal of Molecular Sciences 2016; 17(2) doi: 10.3390/ijms17020225
|
| 15 |
Christine Martinez‐Vinson, Anaïs Lemoine, Yoram Bouhnik, Ben Braithwaite, Audrey Fohlen‐Weill, Janet Addison. PERFUSE. Journal of Pediatric Gastroenterology and Nutrition 2023; 76(4) doi: 10.1097/MPG.0000000000003683
|
| 16 |
Federica Nuti, Gionata Fiorino, Silvio Danese. Adalimumab for the treatment of pediatric Crohn’s disease. Expert Review of Clinical Immunology 2015; 11(9) doi: 10.1586/1744666X.2015.1072048
|
| 17 |
M A Cozijnsen, M van Pieterson, J N Samsom, J C Escher, L de Ridder. Top-down Infliximab Study in Kids with Crohn's disease (TISKids): an international multicentre randomised controlled trial. BMJ Open Gastroenterology 2016; 3(1) doi: 10.1136/bmjgast-2016-000123
|
| 18 |
Marina Aloi, Federica Nuti, Laura Stronati, Salvatore Cucchiara. Advances in the medical management of paediatric IBD. Nature Reviews Gastroenterology & Hepatology 2014; 11(2) doi: 10.1038/nrgastro.2013.158
|
| 19 |
Parambir S. Dulai, Kimberly D. Thompson, Heather B. Blunt, Marla C. Dubinsky, Corey A. Siegel. Risks of Serious Infection or Lymphoma With Anti–Tumor Necrosis Factor Therapy for Pediatric Inflammatory Bowel Disease: A Systematic Review. Clinical Gastroenterology and Hepatology 2014; 12(9) doi: 10.1016/j.cgh.2014.01.021
|
| 20 |
Juan Zhou, Li Li, Jing Luo, Yingtian Yang, Xing Shen. Association between common laboratory indices and IgAV recurrence in children. BMC Pediatrics 2022; 22(1) doi: 10.1186/s12887-022-03657-9
|
| 21 |
|
| 22 |
Mi Jin Kim, Yon Ho Choe. Change in the treatment strategy for pediatric Crohn's disease. Korean Journal of Pediatrics 2010; 53(9) doi: 10.3345/kjp.2010.53.9.830
|
| 23 |
Anne Christine W. Vos, Daniel W. Hommes. Crohn's Disease and Ulcerative Colitis. 2012; doi: 10.1007/978-1-4614-0998-4_44
|
| 24 |
Viktor Wintzell, Henrik Svanström, Mads Melbye, Tine Jess, Ola Olén, Jonas F Ludvigsson, Björn Pasternak. Use of tumour necrosis factor-α inhibitors and the risk of serious infection in paediatric inflammatory bowel disease in Denmark: a nationwide cohort study. The Lancet Gastroenterology & Hepatology 2019; 4(11) doi: 10.1016/S2468-1253(19)30266-3
|
| 25 |
So Yoon Choi, Yiyoung Kwon, Sujin Choi, So Mi Lee, Byung-Ho Choe, Ben Kang. Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn’s disease. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1192827
|
| 26 |
Mi Jin Kim, Yon Ho Choe. Recent Trends of Infliximab Treatment for Crohn's Disease. Pediatric Gastroenterology, Hepatology & Nutrition 2012; 15(1) doi: 10.5223/kjpgn.2012.15.1.19
|
| 27 |
Federica Nuti, Fortunata Civitelli, Silvia Bloise, Salvatore Oliva, Marina Aloi, Giuseppe Latorre, Franca Viola, Salvatore Cucchiara. Prospective Evaluation of the Achievement of Mucosal Healing with Anti-TNF-α Therapy in a Paediatric Crohn’s Disease Cohort. Journal of Crohn's and Colitis 2016; 10(1) doi: 10.1093/ecco-jcc/jjv126
|